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Abstract 
Over the recent years, proteomics has moved from an effort to identify the 
proteins of biological systems to targeted strategy aiming to identify key proteins, 
such as biomarkers that can provide reliable diagnostic and prognostic indicators 
of disease progression, stress condition or treatment effects. By quantitative 
proteomics approach, in fact, it is possible to investigate the protein expression 
level changing due to particular external environmental. This is due to the 
dynamism of proteome that is influenced  to stress conditions, instead of genome 
that result a static biological element. For these reasons in the present thesis were 
development three different method for differential proteomic study in biological 
matrix with mass spectrometry techniques. 
First was a method for carbonic anhydrase II (CA II) absolute quantification in 
human serum. This method is based on high-performance liquid chromatography 
(HPLC)-Chip microfluidic device incorporating a nanoelectrospray source 
interfaced to a triple quadrupole mass spectrometer. The fraction containing CA II 
was isolated by preparative reversed-phase HPLC, and peptides obtained from the 
tryptic digest of the protein mixture were separated by the HPLC-Chip system. 
The multiple-reaction monitoring acquisition mode of a selected suitable CA II 
peptide and peptide internal standard allowed the selective and sensitive 
determination of a CA II. Recovery of the method was 81±10%. A comparison 
among three regression lines type which were obtained by external calibration, 
matrix-matched calibration, and standard addition method, respectively, 
demonstrated that the first one is adequate in obtaining good accuracy and 
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precision. Method quantification limit for CA II in serum was estimated to be 3,7 
pmol/mL. 
Second method was based on a magnetic bead-based platform amenable to high-
throughput protein carbonic anhydrase II (CA II) capture. The key steps in this 
approach involved immunoaffinity purification of the target protein from serum 
followed by on-bead digestion with trypsin to release a surrogate peptide. This 
tryptic peptide was quantified by liquid chromatography–electrospray ionization–
tandem mass spectrometry (LC–ESI–MS/MS) operating in multiple reaction 
monitoring acquisition mode. Using a synthetic peptide standard and a structural 
analogue free-labeled internal standard, the resulting concentration was 
stoichiometrically converted to CA II serum concentration. The analytical steps, 
such as preparation of immunobeads, protein capture, proteolysis, and calibration, 
were optimized. The method was validated in terms of recovery (77%), 
reproducibility (relative standard deviation [RSD] < 12%), and method detection 
limit (0.5 pmol ml/1). The developed method was applied to determining the CA 
II in eight healthy subjects, and the average concentration measured was 27.3 
pmol/ml. 
Third method was based on multidimensional chromatography. These techniques 
have emerged as a powerful tool for the large-scale analysis of such complex 
samples as biological samples. In order to evaluate these separation techniques, 
microgram quantities of protein extracted from mouse heart tissue were 
fractionated by four different chromatographic methods. Regarding peptide-level 
fractionation the first dimension of separation was performed with High-pH 
Reversed-Phase Chromatography (pH-RP) and Strong Cation Exchange 
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Chromatography (SCX). Regarding protein-level fractionation instead C8 Protein 
Reverse Phase (C8-RP Prot) and High Recovery Protein Reverse Phase (hr-RP 
Prot) were used. The second dimension consisted of a reversed-phase nano-HPLC 
on Chip coupled to an electrospray ionization quadrupole time-of-flight mass 
spectrometer for tandem mass spectrometric analysis. The performance and 
relative fractionation efficiencies of each technique were assessed by comparing 
the total number of proteins identified by each method. The peptide-level pH-RP 
and the hr-RP Prot peptide-level separations were the best method, identifying 
1338 and 1303 proteins, respectively. Worst method instead was the peptide-level 
SCX with 509 proteins identified. 
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CHAPTER 1: General introduction 
 
1.1 Proteomics 
Proteins are vital parts of living organisms, as they are the main components of 
the physiological metabolic pathways of cells. The term proteomics was coined in 
the middle of ‘90 in analogy with genomics, and trascrittomics and is defined as 
―The analysis of the entire protein complement expressed by a genome.‖[1].  
Unlike the genome that is constant, the trascrittome and proteome differ from cell 
to cell and may varies with time or cellular conditions. So proteomics may be 
considered the next step in the study of biological systems, after genomics and 
trascrittomics since proteins are the main effectors of most cellular functions.  
Genome and trascrittome studies may be incomplete for several reasons. First, 
often the gene transcription level gives only a rough estimate of its level of 
expression into a protein. In fact in several cases, there is poor or no correlation 
between trascriptome and protein abundance. The mRNA produced in abundance 
may be degraded rapidly or translated inefficiently, resulting in a small amount of 
protein. Second, there are other biological changes that may affect the correlation 
between gene expression and protein synthesis. For instance many transcripts give 
rise to more than one protein, through alternative splicing or alternative post-
translational modifications [2]. 
By proteomics is it possible  to obtain many important information about 
structures and functions of proteins. In particular functional proteomics is 
addressed to the study of cellular compartments, multi-protein complexes and 
signalling pathways. The knowledge of structure or conformational changing of 
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proteins may be of aid in understanding the role of proteins. The most common 
functional proteomics study point out to the analysis of the phosphoproteome by 
means of localization of the phosphorylated residues, and the determination of the 
phosphorylation degree [3,4].  
The post-translational modifications may profoundly affect protein activities. For 
example some proteins are not active until they become phosphorylated. Then  
functional proteomics allow the comprehension of different protein activities 
depending to their phosphorylation state. 
At present time, protemics is in high development also because it allows the 
knowledge of the molecular effects due to particular cellular conditions.  
This application is employed by expression proteomics, which aims to measure 
the changing of protein levels. Indeed, by applying comparative characterizations, 
proteomics is a powerful tool for finding out which particular proteins are 
involved in an organism reaction mechanism when environmental conditions 
change. Then expression proteomics is science that show the exactly cellular 
phisiologic state. For these reasons it may recover many application in several 
scientific fields.  
One of the most promising application of proteomics is the identification of 
potential new drugs for the treatment of disease. This relies proteome information 
to identify proteins associated with a disease, also called biomarker,  which can be 
used as targets for new drugs.  In addition protein may be used to diagnose 
disease. Under pathological conditions some proteins may be up or over-
expressed. So by studying the proteins expression level changes it is possible to 
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find a particular protein related to pathologic state. There are more example of 
applications of disease biomarker for medical diagnosys. 
 
1.2 Analytical techniques in proteomics 
Over the past two decades, mass spectrometry (MS) has become an important tool 
for the analysis of proteins [5,6]. One current method for the analysis of protein 
mixtures is proteolytic digestion followed by Liquid Chromatography-Tandem 
Mass Spectrometry (LC-MS/MS). This approach overcomes many difficulties 
associated with protein mixture MS analysis [7]. MS/MS analysis has been 
particularly effective because the data can be directly used to identify peptides and 
subsequently infer which proteins are in the mixture [8]. This type of approach for 
the analysis of protein mixtures is often referred to as ―shotgun‖ proteomics. 
Because increasingly complicated biological structures are studied by MS/MS, the 
need for more powerful and highly resolving separation methods has grown.  
Infact, proteins are identified by mass-to-charge ratios of peptides and their 
fragments and sufficient separation is required for unambiguous identifications. 
Therefore proteins MS is closely linked to and depends largely on the separation 
technologies to simplify incredibly complex biological samples prior to analysis 
of the mass. Front-end separation is also required to detect low-abundance species 
that would otherwise be overshadowed by a higher abundance signal. Therefore, 
both accuracy and sensitivity of a mass spectrometric experiment rely on efficient 
separation. There is a very strong conceptual link between chemical separation 
and MS in which the latter is viewed as the mass resolution dimension of 
molecules separation [5]. Selection of appropriate separation methods is often the 
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first step in designing the proteomic application. Two major approaches to 
separation widely used in proteomics are gel based and gel free. Two-dimensional 
polyacrylamide gel electrophoresis (2D PAGE) is the historic centerpiece of the 
gel-based separation methods [9-12]. There are many excellent reviews that cover 
2D PAGE and gel-based approaches to proteomics [13-16]. Gel-based methods 
have been traditionally used with pulsed ionization MALDI instruments in which 
the protein band can be excised, digested, and off-line sampled with MALDI 
source [17]. The limitations of 2-DE in detecting low abundance proteins, very 
small or large proteins, as well as basic and membrane/hydrophobic proteins [18-
20], as well as difficulties with automation of the process, have forced researchers 
to look for other methods of protein separation, such as multidimensional liquid 
chromatography (MDLC). MDLC is by no means a new concept and has a long 
history, it has been enjoying a renaissance in proteomics [9]. MDLC combines 
two or more forms of LC to increase the peak capacity, and thus the resolving 
power, of separations to better fractionate peptides prior to entering the mass 
spectrometer. Furthermore for adequate representation of the proteome, only 
multidimensional separation techniques can provide resolving capability of 
thousands of protein species and have proven to be superior to one-dimensional 
approaches. These techniques have emerged as a powerful tool for the large-scale 
analysis of such complex samples [21-24]. It better resolves peptides differing in 
charge and hydrophobicity to minimize ion suppression and improve ionization 
efficiency, and it simplifies the complexity of peptide ions entering into the mass 
spectrometer to minimize undersampling. This last aspect is important because the 
tandem MS process is driven by data-dependent-acquisition (DDA) and has a 
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finite cycle time. A higher peak capacity and better resolving power improve the 
acquisition of data and can lead to a better representation of the proteins in the 
mixture and permit the identification of low-abundance proteins [21,22,25,26].  
For example various techniques prefractionation orthogonal on the level of protein 
and peptide level have been utilized for the characterization of part of yeast 
proteome leading to the identification of thousands of proteins [27,28]. 
 
1.3 Proteins or Peptides Level Separation? 
The protein-level and peptide-level separations have relative advantages and 
disadvantages. Proteins are sensitive to precipitation upon exposure to high salt 
concentrations, to basic pH values, and organic solvents. Peptides, on the other 
hand, are relatively stable in solution and generally do not exhibit solubility 
issues. However, peptide-level separations also have limitations, including the 
scattering of tryptic peptides from a single parent protein into multiple fractions, 
which can potentially reduce protein identification scores. Furthermore for 
adequate representation of the proteome, only multidimensional separation 
techniques can provide resolving capability of thousands of protein species and 
have proven to be superior to one-dimensional approaches. 
 
1.4 Multidimensional  Chromatographic Techniques 
Currently in the literature are given a variety of multidimensional combinations 
that lead to an increase in the resolving power of the technique [29,30]. These 
methods can use different chromatographic techniques and a different number of 
dimensions. There are important factors to be considered as the amount of time 
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required for analysis, compatibility with MS buffer used for the chromatographic 
separation, and the effective integration of two dimensions. Usually the last stage 
of separation, which usually is the step directly interfaced to a mass spectrometer, 
is the RPLC, which can provide high resolution, desalting of samples, and the 
compatibility of the phases with the ESI source and MS detection. The basis of 
RP method is the hydrophobic interaction between peptides and stationary phase. 
The stationary phase is the most common C18 covalently linked with a basic 
material of silica, these phases are called RP, C18, silica or octadecyl (better 
known as ODS). Peptides are loaded onto an RP column in a solution with a low 
content of organic phase, which allows on-line desalting and concentration at the 
same time. During the chromatographic run is gradually increased the amount of 
organic modifier in the mobile phase so that the peptides may elute according to 
the strength of hydrophobic interactions with the stationary phase. The peptides 
separation by RP chromatography has been widely studied in recent decades and 
significant progress has been made in this technique [31]. Because of its 
separation efficiency, superior to other LC techniques, and its excellent 
compatibility with ESI, RP remains an important method of peptides or protein 
separation. An important consideration for the development of multidimensional 
separations is the orthogonality of coupled techniques. The resolution can be 
maximized by combining chromatographic methods based on different principles 
of separation. While the RP chromatography is mainly used as second dimension 
in proteomics applications, a variety of chromatographic techniques were used for 
the first dimension. The most commonly used techniques are exclusion 
chromatography, strong cation exchange (SCX) and strong anion exchange 
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[30,32-36]. Some factors are important in the first dimension, should have a large 
carrying capacity, to be configurable with the second dimension, and should use a 
solvent compatible with the second mode. Many of the methods listed above 
reflect these criteria, while others are more suited for off-line. One of the most 
widely used combinations for MDLC is SCX and RP. SCX keeps peptides based 
on electrostatic interactions. Sulfonyl end groups of the resin coat the surface and 
create a strong negative charge that is largely resistant to pH changes. Peptides are 
loaded onto an SCX column with a low pH buffer (3-4), which permits, block the 
dissociation of peptide‘s carboxylic groups and promote interactions between the 
protonated basic amino acid residues and the sulfonate groups of SCX resins. 
Peptides are eluted by increasing the strength of the salt buffer, which disrupts the 
interaction between peptides and sulfonate groups. To break the stronger 
interaction between peptide and SCX resin, the greater salt concentration is 
needed. Also experimentally showed that the phase SCX has additional features, 
such as hydrophobicity [37]. To minimize the hydrophobicity role and to facilitate 
the peptides denaturation, 10-15% of organic modifier is often added to the 
elution buffer. Fractionation of electrostatic interaction provides a degree of 
orthogonality to RP separation and therefore is an excellent complement. 
Multidimensional techniques discussed above can be coupled in off-line mode or 
in on-line mode. The first is the simplest and provides the fractions collection 
after the first dimension and a further separation of these with the second 
dimension interfaced to mass spectrometer. On-line mode, instead, is refers to a 
system in which the transfer of the analyte between the first and second dimension 
is automated and does not involve any disruption of flow [38]. To do this, 
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generally a switching valve is placed between the two dimensions. The main 
advantages of these mode are the ease of automation and a reduced risk of sample 
loss and contamination than off-line mode. Use of switching valves often involves 
use of a intermediate column such as a trap for on-line sample desalting and this 
makes the configuration relatively flexible compared to the integrated column. 
However, the passage of the sample in the switching valves and then exposure to 
surfaces and to additional connections can lead to loss of analyte. MDLC in on-
line mode can also be performed using biphasic column. This integrated system is 
a simple system where the first 10-15 cm of the column is packed with RP 
material, followed by ~ 3-5 cm of SCX material. A final portion of RP can be 
added to act as desalting phase or as a further separation phase [39,40]. Peptides 
are loaded manually onto the column [41]. The manual loading of samples 
directly onto the column minimizes any loss of analyte that could occur through 
the valve system. The end of the capillary column RP usually forms a conical tip 
end so that the column serves as the ESI emitter, so as to have a minimum 
postseparation dead volume [42]. Multidimensional separation is achieved by 
passing a series of buffers in the column [32]. The peptides related to the SCX 
phase are first eluted with a 2-5 minutes pulse of saline solution and second are 
separated by a RP gradient. A second pulse of saline solution is then used to move 
another population of peptides on the RP column, this process is repeated a 
number of times. Because the sample transfer between phases occurs within a 
single section of the column, the dead volume becomes negligible. Generally, the 
on-line approaches are ideal when the sample available is limited and the losses 
must be minimized. 
  17 
1.5 Aim of the thesis 
The aim of this research was to develop three different method for differential 
proteomic study in biological matrix with mass spectrometry techniques. 
First was a method for carbonic anhydrase II (CA II) absolute quantification in 
human serum. This method is based on high-performance liquid chromatography 
(HPLC)-Chip microfluidic device incorporating a nanoelectrospray source 
interfaced to a triple quadrupole mass spectrometer and we applied a label-free 
absolute quantification method based on quantitative equivalence between the 
protein and a selected peptide coming from protein tryptic digestion. Second 
method was based on a magnetic bead-based platform amenable to high-
throughput protein carbonic anhydrase II (CA II) capture. In the current study, in 
fact, a Protein G magnetic bead-based antibody platform is proposed for the 
selective enrichment of CA II in human serum, followed by its accurate and 
reliable quantification by a label-free procedure performed on a less 
technologically sophisticated LC–ESI–tandem mass spectrometry (MS/MS) 
system. Third method was based on multidimensional chromatography. These 
techniques have emerged as a powerful tool for the large-scale analysis of such 
complex samples as biological samples. In order to evaluate these separation 
techniques, have been systematically compared the following chromatographic 
techniques: offline SCX combined with RP, mixed-mode pH RP-RP for peptide-
level separation, and RP with two different columns for protein-level separation. 
We have also compared the following identification parameters: total proteins 
identified, total number of peptides identified (including redundant 
identifications), total number of unique peptides (only nonredundant 
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identifications), average protein sequence coverage, and protein E-value 
(probability score). 
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CHAPTER 2: HPLC-CHIP coupled to a triple quadrupole mass 
spectrometer for carbonic anhydrase II quantification in human 
serum 
 
2.1 Introduction 
Over the recent years, proteomics has moved from an effort to identify the 
proteins of biological systems to targeted strategy aiming to identify key proteins, 
such as biomarkers that can provide reliable diagnostic and prognostic indicators 
of disease progression or treatment effects. However, till now, this tool has been 
only partly exploited. Rapid immunotest development and clinical validation are 
time consuming and costly steps which restrict the new biomarker adoption in 
clinical praxis. Due to its flexibility, mass spectrometry (MS) may constitute a 
more accessible analytical tool for preclinical protein biomarker studies. However, 
it remains difficult to identify biomarkers using conventional proteomic 
approaches because of their low abundance [43]. In addition to the initial 
identification of phenotypic expression and protein characterization, a key 
parameter in proteomic analysis is the ability to quantify proteins of interest. To 
date, a majority of the quantitative proteomic analyses have been performed using 
stable isotope labeling strategies such as isotope coded affinity tag [44], isobaric 
tags for relative and absolute quantitation (iTRAQ™) [45], stable isotope labeling 
by amino acids in cell culture [46], 
18
O labeling [47,48], and stable isotope 
standards with capture by anti-peptide antibodies [49,50]. These methodologies 
require complex, time-consuming sample preparation and can be relatively 
expensive [51]. One of the most powerful and used proteomics approaches for 
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low-abundance protein identification involves the ultrasmall-bore liquid 
chromatography coupled to nanoelectrospray MS (nano-LC-MS). Recently, it has 
been presented a microfabricated approach to nano-LC that integrates all the 
components on a single LC Chip, eliminating the need for conventional LC 
connections [52]. LC-Chip-MS technology allows by itself multi-dimensional LC 
because it has an integrated sample enrichment column, a reversed phase (RP) LC 
separation column, an electrical contact for electrospray (ESI) and a nano-ESI tip. 
Miniaturization has radically reduced sample size and cost, has improved 
sensitivity, and has increased speed [53]. Carbonic anhydrases (CAs) represent a 
group of zinc metalloenzymes that catalyze the reversible hydration of carbon 
dioxide to bicarbonate [54]. In mammals, CAs occur in 14 different isoforms [53] 
that differ in their subcellular localization; for example, CA I is cytosolic, CA V is 
mitochondrial, while CA VI is membrane associated [55–58]. CAs are involved in 
important physiological processes such as, for example, transport of CO2 [54], 
intracellular pH control [59], renal and male reproductive tract acidification, 
electrolyte secretion, and formation of gastric acids [60–62]. The carbonic 
anhydrase II (CA II—molecular weight ca. 29 kDa, and theoretical pI 7.5) [63] is 
expressed in a wide variety of normal cells including erythrocytes (where it is the 
main isozyme of the CA family), pancreatic, as well as kidney and gastrointestinal 
tract epithelial cells. Finally, CA II has multiple, complex functions in the human 
brain where its deficiency has been associated with pathological consequences 
such as mental retardation and brain calcification [64,65], as well as Down 
Syndrome (DS) [54,63] 
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and Alzheimer‘ disease [63]. Increased CA II levels in some brain tissues have 
been found in infant with DS, and a marked CA II up-regulation in 
oligodendrocytes subject to demyelinating condition in humans has been also 
reported [66,67]. In previous researches, CA II purification has been performed by 
affinity chromatography followed by mono-dimensional gel electrophoresis 
[57,68]. Sensitive competitive enzyme-linked immunosorbent assay [56], two-
dimensional gel electrophoresis followed by matrixassisted laser 
desorption/ionization time-of-flight (MALDITOF) MS [21], and Western blot [54, 
55] have been adopted for its detection and to assess relative concentration in 
human [55] and equine [56] blood erythrocytes, as well as in human [63] and 
mouse brain [54]. To our knowledge, there are no papers dealing with the CA II 
determination by means of LC/ESI-MS in real samples. In addition, with the 
exception of the erythrocytes, CA II levels have been investigated only in 
postmortem [54] and tumor specimens [69]. As a consequence of the cellular 
expression, CA II might be also present in serum, although low concentrations 
would be expected in normal, healthy subjects. The aim of this research was to 
develop a method for the CA II absolute quantification in human serum. For this 
purpose, we applied a label-free absolute quantification method based on 
quantitative equivalence between the protein and a selected peptide coming from 
protein tryptic digestion. In a previous work [70] dealing with troponin T 
quantification in mouse heart tissue, small-bore highperformance liquid 
chromatography (HPLC) coupled with pneumatically assisted ESI-triple 
quadrupole (QqQ) MS/MS, operating in multiple reaction monitoring (MRM) 
mode, and the matrix-matched calibration curve were used. In this work, the 
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capability and the high sensitivity of the automated HPLC-Chip technology 
coupled with a QqQ mass spectrometer was exploited to identify and quantify CA 
II in serum. Although present at very low levels, due to the low matrix effect 
allowed by this kind of instrument, it was demonstrated that the external 
calibration can be used for CA II quantification in serum.  
 
2.2 Experimental part 
2.2.1 Reagents and chemicals 
Bradford reagent and trifluoroacetic acid (TFA) were obtained from Sigma-
Aldrich (St. Louis, MO, USA). Tris (hydroxymethyl)aminomethane, 1,4 
dithiothreitol (DTT), iodoacetamide (IAA), and urea were purchased from GE 
Healthcare (Uppsala, Sweden). All organic solvents were the highest grade 
available from Carlo Erba Reagents (Milan, Italy) and were used without any 
further purification. Ultrapure water was produced from distilled water by a Milli-
Q system (Millipore Corporation, Billerica, MA, USA). C18 silica Bond Elut 
EWP (Extra Wide Pore) was obtained from Varian (Palo Alto, CA, USA). 
Cellulose Acetate Spin Filters (0.22 μm pore size) were purchased from Agilent 
Technologies (Wilmington, DE, USA). Protein LoBind tube were obtained from 
Eppendorf (Hamburg, Germany). Modified porcine trypsin, sequencing grade, 
was commercialized by Promega (Madison, WI, USA). A Sequazyme peptide 
mass standards kit, with the following composition: bradykinin fragment 1-5 
(573.3150), angiotensin II human (1046.5424), neurotensin (1672.9176), ACTH 
fragment (2465.1989), insulin B chain oxidized (3494.6514), was obtained from 
LaserBio Labs (Sophia Antipolis Cedex, France). A α-cyano-4-hydroxycinnamic 
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acid (CHCA) for MALDI-TOF analysis was obtained from Applied Biosystems 
(Concord, ON, Canada). Synthetic peptide standards (5 mg each, certified title 
≥95%), corresponding to GGPLDGTYR (CA II-specific peptide) and 
GGPLEGTYR (internal standard, IS), respectively, were purchased from the 
CRIBI Center (Padova University, Italy). Their masses were verified by 
MALDITOF MS instrument (Applied Biosystems), and no contaminants were 
detected. Peptide stock solutions were prepared in 0.1% TFA at 1 g/L and stored 
at −20°C. The human CA II standard (≥80%) was purchased from Sigma-Aldrich, 
reconstituted with 0.1% TFA at 1 g/L, and storedat −80°C. Its actual title was 
tested by the Bradford assay and was found to be 85±5%. 
 
2.2.2 Samples 
Eight human serum samples were obtained from San Raffaele Hospital (Roma) by 
venipuncture of healthy male and female volunteers (age between 20 and 40), 
with collection in a Becton Dickinson Vacutainer tube (VWR, West Chester, PA) 
with serum separator tube gel and BD clot activator. After clot formation, the 
sample was 
centrifuged at 1,000×g for 15 min. The serum was removed and aliquots stored at 
−80°C. All serum samples were checked by Hemoglobin Ittero Lipemia test on 
Architect C 8000 system (Abbott, Irving, TX, USA) to verify absence of 
hemolysis. Total time for serum processing was less than 60 min. A protease 
inhibitor cocktail, Complete (Roche Biochemicals, Indianapolis, IN, USA) was 
added to serum to reduce proteolytic degradation. 
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2.2.3 Sample preparation 
Carbonic anhydrase II isolation by RP-HPLC  
The serum sample was transferred to a 0.22 μm pore size spin filter for removing 
particulates by centrifugation (centrifuge from ALC-Milan, Italy) at 16,000×g for 
1 min at room temperature. Thereafter, 20 μL of filtered serum were diluted to 1 
mL with a solution of water, urea, and acetic acid (final concentration, 6 mol/L 
urea, 1% v/v acetic acid). The solution was permitted to equilibrate for at least 30 
min before RP-HPLC separation. Liquid chromatography was performed using 
Perkin-Elmer series 200 pumps (Norwalk, CT, USA), including a vacuum solvent 
degassing unit, and coupled to a UV detector (Varian-Walnut Creek, CA, USA). 
CA II chromatographic isolation was carried out on a Zorbax 300SBC8 column 
(150×4.6 mm i.d., 300 Å pore size, 5 μm particle size) from Agilent Technology 
(Santa Clara, CA, USA) with a securityguard octadecylsilica, 4×3 mm i.d. 
precolumn, supplied by Phenomenex (Torrance, CA, USA). The column was 
maintained at 50°C in a thermostatted oven (Timberline Instruments, Boulder, 
CO, USA). The injection volume was 100 μL of diluted sample (ca. 120 μg of 
proteins estimated using Bradford assay). Compounds were separated using a 
gradient of acetonitrile 0.08% (v/v) TFA (B) and water 0.1% (v/v) TFA (A). The 
gradient, at a flow rate of 0.5 mL/min, started with 30% eluent B and was linearly 
increased to 80% in 100 min. The eluted proteins were monitored at 215 nm by 
UV detection. A fraction was collected from 29.0 to 30.5 min based on the CA II 
retention time obtained by chromatographic analysis of 35 pmol of CA II standard 
solution in urea and acetic acid. Then the fraction, collected in a protein LoBind 
tube, was lyophilized (Thermo Fisher Scientific, Waltham, MA, USA) and stored 
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at −80°C. The chromatographic profile relative to a serum sample fortified with 
20 nmol/mL CA II standard is reported in Fig. 1.  
 
Enzymatic digestion and peptide desalting  
The lyophilized protein fractions were redissolved with 100 μL of a solution of 
100 mmol/L Tris/HCl, 6 mol/L urea, pH=7.8. The sample was reduced with 200 
mmol/L DTT, alkylated with 200 mmol/L IAA, diluted to 1 mL, and then digested 
with 200 ng trypsin at 37°C for 20 h. The digestion was quenched by adding 1% 
(v/v) TFA. Then, 50 μL of a 3-pg/μL IS solution was added to the tryptic digest to 
be carried through all further processing. Peptides were desalted using a C18 
silica cartridge (2 mL polypropylene tube with 50 mg of the adsorbent phase). 
Before use, the cartridge was attached to a vacuum manifold apparatus 
(Millipore), washed with 2 mL of water/acetonitrile (50:50, v/v), and equilibrated 
with 2 mL of solution consisting of 100 mmol/L Tris/HCl, 0.6 mol/L urea, pH 7.8, 
and 0.1% (v/v) TFA. The tryptic digest was passed through the C18 silica 
cartridge, and salts were removed with 1 mL of water 0.1% (v/v) TFA. Finally, 
the peptides were slowly eluted with 500 μL of water/acetonitrile (20:80, v/v), 
0.1% (v/v) TFA, and collected in a 2 mL tube (Protein LoBind). Thereafter, 
solvents were removed in a water bath at 37°C under a nitrogen stream, and the 
sample was successively reconstituted with 200 μL of water/acetonitrile (95:5v/v), 
0.1% (v/v) formic acid. 
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Fig. 1: Reversed-phase chromatographic profile relative to a diluted serum sample 
fortified with 20 nmol/mL carbonic anhydrase II standard. Zorbax 300SB-C8 
column (150×4.6 mm i.d., 300 Å pore size, 5 μm particle size), T=50°C. UV 
detector at 215 nm 
 
2.2.4 LC/ESI-MS/MS analysis 
HPLC-Chip-MS system 
Liquid chromatography was performed using an Agilent series 1200 instrument 
(Agilent Technologies, Waldbronn, Germany) consisting in 1200 Series 
nanopump with degasser; 1200 Series capillary pump; 1200 Series thermostatted 
microwell-plate autosampler, and HPLC-Chip-MS interface. The following 
components are integrated onto the HPLCpolymeric Chip (G4240-65001-Agilent 
Technologies, Santa Clara, CA, USA): a 40-nL enrichment column packed with 
ZORBAX 300 SB-C18, 5 μm particle size; a 50 μm (d)× 75 μm (w)×43 mm (l) 
RP-LC separation column packed with ZORBAX 300 SB-C18, 5 μm particle size; 
the nanospray emitter (50 μm i.d.). The HPLC-Chip is inserted into the HPLC-
Chip-MS interface. It mounts directly on the MS source and includes a miniature 
camera for spray visualization, the HPLC-Chip loading and ejection mechanism, a 
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microvalve for flow switching, and fluid connection ports for the nano-LC and 
microwell-plate autosampler. The nanospray emitter was connected to the Agilent 
6410 QqQ equipped with an ESI source. The Agilent Mass Hunter ChemStation 
software (version B01.03) was used for data acquisition and processing. 
 
Chromatographic conditions 
Solvent A was water, and solvent B was acetonitrile, both containing 0.1% (v/v) 
formic acid. The mobile phase gradient, started with 5% B, reached 31% B after 6 
min, then was brought to 95% within 3 min and held constant for 1 min to rinse 
the column. Finally, the starting condition was restored over 1 min and the 
column re-equilibrated with a post run time of 2 min. Flow rate was set to 300 nL/ 
min. Enrichment of the analytes prior to gradient start was performed by capillary 
pump running at 4 μL/min 0% B connected to a μ-well plate autosampler for 
sample loading on the Chip. A 2.5-μL aliquot of digested sample was loaded onto 
the Chip devise by the autosampler. The intelligent sample loading feature of the 
HPLC-Chip ChemStation menu was used. This feature allows sample loading 
onto the enrichment column during the pre-run time. After sample enrichment was 
completed, the rotary valve interface was switched to the load position and then 
elution gradient started. 
 
Mass spectrometric conditions 
ESI stability was tested by delivering a test sample at a constant pressure and by 
monitoring the MS signal. The MS response of a 0.5 pg/μL reserpine solution was 
visualized both as the total ion chromatogram and the extracted ion mass m/z 
609.2. The signal exhibited stability of 2% at a flow rate of approximately 114 
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nL/min. Ionization and mass spectrometric conditions were optimized for both 
CA II-specific peptide and IS by infusing at 0.6 μL/min flow-rate a 100 pg/μL 
solution in water/acetonitrile 95:5 (v/v) containing 0.1% (v/v) formic acid, using a 
MS calibration and diagnostic Chip (G4240- 61001—Agilent Technologies). The 
analyses were performed in positive ionization mode with a capillary voltage set 
at 1,750 V and a delta electro multiplier voltage of 500 V. The drying gas flow 
was 4 L/min of nitrogen, and the drying gas temperature was 350°C. Because the 
HPLC-Chip interface uses an enclosed source design to eliminate background 
contamination from the laboratory air, to achieve low background conditions, an 
additional 1.5 L/min of filtered air was added to the drying gas. The position of 
the nano-ESI Chip tip was optimized for low spray flow rate to produce a good 
direct ESI spray under the correct voltage and so to achieve high MS sensitivity 
and a stable spray. Peptide diprotonated molecules [M + 2H]
2+
 (m/z 468.4 and 
475.4) were mass-selected by the first quadrupole and fragmented. Two suitable 
transition pairs were chosen for acquisition in MRM mode for both CA II-specific 
peptide and IS peptide. The fragmentor and collision energy (CE) were optimized 
for each ion. Identification was performed on the basis of retention times and 
spectra matching respect to standards. Parameters are summarized in Tab. 1. The 
Chip can be used for many hours, even after several hours of no-use, in contrast to 
standard commercial nano-ESI tips. 
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Peptide 
Retention 
time 
(min) 
Precursor 
ion 
MRM 
transition 
Relative 
abundance (%) 
GGPLDGTYR 
(CA II marker) 
5.04 [M + 2H]
2+
 
468.4→611.4 53 
468.4→411.4 100 
GGPLEGTYR 
(Internal standard) 
4.97 [M + 2H]
2+
 
475.4→625.4 100 
475.4→418.2 92 
 
Tab. 1: Instrumental parameter settings under Multi Reaction Monitoring 
conditions for the two peptides (CA II specific peptide and internal standard 
peptide 
 
Calibration 
Standard solutions for calibration were prepared by drawing the appropriate 
volume of the CA II-specific peptide GGPLDGTYR working standard solution, 
50 μL of a 3- pg/μL IS peptide GGPLEGTYR working standard solution, 
evaporating at 37°C under a gentle N2 stream. Then the solution was reconstituted 
with 200 μL of the starting chromatographic mobile phase in order to obtain nine 
concentration levels in the range of 0.01–50 pmol/mL. Volumes of 2.5 μL of 
standard solutions were injected. The ion current profiles of the selected transition 
pairs for the two peptides were extracted from the LC-MRM dataset, the resulting 
peak areas were measured, and the ratios of CA II specific peptide to IS peptide 
areas were plotted. The matrix-matched calibration line was constructed by using 
a serum pool obtained by mixing 25 μL serum aliquots from the eight healthy 
subjects. As each 2 μL of sample give rise to a 200 μL of final extract, for matrix-
matched calibration line, three extracts were mixed and subdivided in 50 μL 
aliquots, processed as reported above, and spiked with the suitable standard 
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amounts (GGPLDGTYR and IS standard solutions) in order to obtain the same 
concentrations as for the external calibration. After evaluating the analyte mean 
concentration by using the matrix-matched calibration line, the standard addition 
method was also performed. Two hundred microliters of the processed sample 
were subdivided in four aliquots of 50 μL each. One of them was analyzed 
unspiked, while 20, 30, and 40 pg, respectively, of the CA II-specific peptide 
(corresponding to 43, 64.5, and 86 pmol/mL in serum) were added to the 
remaining three aliquots before injection. All samples were run in triplicate, 
results were averaged, and the unweighed regression lines were constructed. In a 
separate experiment, the linear range was tested by an eight-point calibration 
graph. The response of ESI-MS/ MS was linearly related to the injected amounts 
up to 40 ng (3 nmol/mL serum), (R2>0.9985). 
 
Recovery experiments and statistical evaluation 
Absolute recoveries (for both the whole procedure and the selected representative 
peptide), and analytical recoveries were evaluated separately. Eight human serum 
aliquots were pooled and then split again into 12 aliquots (divided in three sets of 
four aliquots each). Then, three aliquots of the first set were fortified with suitable 
volumes of the CA II standard solution to obtain the spiked concentration levels 
of 103, 206, and 345 nmol/mL, respectively, while the fourth aliquot was kept 
unspiked. The criterion adopted for fortification was spiking at three different 
levels: about twice, four, and ten times the amount of endogenous protein 
(roughly evaluated by using external calibration). Afterwards, all the first set 
aliquots were handled as described above, but the IS was added just before 
injection. The second set samples were submitted to HPLC fractionation, 
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liophylization and tryptic digestion, then molar amounts of the representative 
peptide corresponding to those used for intact CA II fortifications were added to 
three aliquots of second set, while the fourth was left unspiked. The IS was added 
to the four aliquots just before injection. The third sample set was handled as the 
second one with the difference that the IS was added after tryptic digestion. 
Analyses of spiked and unspiked samples were replicated six times. Recoveries 
were assessed for each concentration by measuring the resulting peak area of the 
CA II-specific peptide (GGPLDGTYR), calculating the peak area ratio relative to 
that of the IS, subtracting the mean ratio value for unspiked samples and 
comparing this result with that obtained by adding both CA II-specific and IS 
peptides just before injection. Statistical evaluation was performed by the analysis 
of variance (p=0.05). 
 
Peptide adsorption to surfaces 
Peptide adsorption is an important attribute to take into consideration also for 
reproducibility. Because the steel passivation did not allow further peptide 
adsorption, reproducibility of LC-MS data was improved by periodically treating 
the autosampler needle (the only metallic components of the LC system) with a 
water/nitric acid solution 50:50 (v/v). To reduce peptide adsorptive processes, 
suitable storage vessels were used (protein low-retention tubes) [70]. 
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2.3 Results and discussions 
2.3.1 CA II-specific peptide and IS selection 
After the RP-HPLC separation step, the sample complexity was still very high. 
When in proteomic research identification of proteins depends on identification of 
peptides resulting from enzymatic digests and the concentration of a selected 
peptide is stoichiometrically related to the concentration of intact protein [71–73], 
the choice of the target peptide appears crucial. Figure 2a, b report the MALDI-
TOF spectra obtained by analyzing 0.2 nmol/mL CA II standard solution, and a 
serum sample extract spiked with the same concentration, respectively. The most 
abundant peptides coming from CA II tryptic digestion are indicated by their m/z 
values. Among tryptic cleavage peptides of CA II, GGPLDGTYR (corresponding 
to 81–89 sequence) was selected as the protein marker. In fact, this peptide amino 
acid sequence is associated exclusively to CA II; its signal intensity was 
reproducible and does not contain any reported posttranslational modification 
sites, thus its monoisotopical mass of 934.5 Da is not subjected to variations. 
Moreover, a preliminar LC/ESI-MS analysis of peptide mixture deriving from CA 
II enzymatic digestion showed an intense ion current corresponding to the 
diprotonated GGPLDGTYR molecule. The synthetic peptide GGPLEGTYR, 
having chemical and physical properties very similar to those of GGPLDGTYR, 
was chosen as IS. In fact, GGPLEGTYR structure (monoisotopic molecular mass 
of 948.5 Da) differs only for one amino acid (a glutamic acid residue instead of an 
aspartic acid residue) from GGPLDGTYR structure and is absent in unspiked 
samples. In this way, the use of a labeled peptide for protein quantification could 
be avoided. The advantages and limits of non-isotopically labeled IS has been 
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discussed previously [70] 
 
 
 
Fig. 2: MALDI-TOF spectra of trypsin digest. a 0.2 nmol/mL carbonic anhydrase 
II standard solution; b 0.2 nmol/mL CA II added to a serum sample 
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2.3.2 Sample preparation optimization 
Complex serum protein samples were fractionated by RPHPLC. Solvent 
composition, flow rate, and gradient profile were optimized for CA II isolation 
from the serum most abundant proteins in a relatively short run time. By this 
separation, it was possible to select a narrow fraction according to the retention 
time (tR) of the standard protein. By injecting 1 μg of CA II, both standard and 
added to the serum samples, the chromatographic peak base width was ca. 40 s 
(see Fig. 1). Retention time reproducibility was attained by thermostatting the 
column; however, to assure a total protein recovery, its corresponding fraction 
was collected over 1.5 min. Identification of CA II was achieved only in the 
collected fraction by peptide mass fingerprinting of its tryptic digest, performed 
by a MALDI-TOF instrument. Considering that the IS can operate only after the 
peptide generation, it is possible to directly correlate target peptide amount to the 
parent protein amount only when the enzymatic cleavage gives high and 
reproducible yields. The amount of trypsin to be added to the serum fraction 
containing CA II was optimized by maximizing the target peptide peak area in a 
series of experiments accomplished in quadruplicate on aliquots of a purified 
serum pool. Two hundred nanograms trypsin assured the largest peptide 
generation which did not increase further on by increasing the trypsin amount. 
Absolute recovery of CA II for the whole procedure was performed by spiking 
serum samples with the standard, at three concentration levels as described in the 
―Experimental‖ section (first set of samples). The overall absolute mean recovery 
for the method was 52% with relative standard deviation not larger than 12% and 
was not dependent on the fortification levels tested. Peptide desalting and solvent 
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exchange steps were also very important for mass spectrometric performances (in 
particular signal suppression and reproducibility). Because the commercial zip 
tips for peptide mixture desalting have a low sample size throughput, 50 mg C18 
(large pore) solid-phase extraction cartridges were preferred. The elution 
optimization has been described in a previous work [74]. The absolute mean 
recovery for the steps involving the selected peptide was evaluated by adding the 
peptide standard at three concentration levels after protein digestion and the IS 
just before injection (second set of samples). The peptide recovery was 65% with 
relative standard deviation not larger than 8% and was independent from the 
fortification levels tested. As expected, the third set of samples gave a mean 
recovery of 82% with relative standard deviations less than 15%. Overall recovery 
experiments demonstrated that the procedure critical step is the peptide desalting 
and evaporation/reconstitution, while the digestion step yield was about 80%, and 
recovery from chromatographic purification was about 100%. 
 
2.3.3 Chromatographic performance of the HPLC-Chip 
The advantages of HPLC-Chip-MS with on-Chip chromatography and spray tip in 
proteomic research have been discussed previously [75,76]. In Chip, all 
connections are ports rather than tubes, volumes are only a few nanoliters, and 
this minimizes the dead volumes, resulting in reduced band dispersion. Moreover, 
surface areas and contact surfaces are inert polyimide in place of steel or glass, 
thus reducing the chemical activity with peptides. As the band broadening is not 
longer due mainly to dead volumes, the mobile phase flow rate may contribute 
significantly to resolution. The HPLC-Chip device can be operated in the flow 
rate range from 100 to 400 nL/min [52]. The LC flow rates delivered by the 
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nanopump during gradient elution were set to 100, 150, 200, 300, and 400 nL/min 
and 2.5 μL of 34 fmol/mL CA II standard digest was injected three times in each 
run. Although the highest MS detection sensitivity could be achieved at 100 
nL/min, reduced separation efficiencies were observed at this flow rate. Moreover, 
in agreement with previously reported results [52], by increasing the flow rates up 
to 300 nL/min, the sample throughput increased without significant increase in 
limit of detection. Another important consideration about Chip technology is the 
ruggedness and ease of operation of the system. In our hands, the nano-LC-Chip-
MS system was operated in an uninterrupted manner for more than 600 injections 
of complex proteins digests on a single Chip without any noticeable performance 
degradation. 
 
2.3.4 Chip-nano-ESI-MS/MS condition optimization 
Nano-ESI-MS/MS detection was essential to ensure the necessary limit of 
quantification (LOQ) and sensitivity for serum CA II determination which cannot 
be obtained by a conventional ESI source. For robust, sensitive, and reliable 
quantitative determination of target peptides, the Chip device was coupled with a 
QqQ mass spectrometer working in MRM mode. As expected [77] in infusion 
experiments, for both peptides the double-charged molecules (m/z 468.4 and 
475.4) gave a more intense signal in the mass spectrum than the monoprotonated 
molecules (m/z 935.4 and 949.5, respectively). Moreover, when selecting the 
mono-charged molecule as precursor in MRM acquisition mode, fragmentation 
occurred at high CE, and the relative abundances of transition pair signals in the 
spectrum showed a great variability. Thus, diprotonated molecules were selected 
as parent ions. Operating at the optimal instrumental conditions for [M + 2H]
2+
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detection, the [M + H]
+
 signal was not detectable in the spectrum. In product ion 
experiments, the two most intense 
fragment ions of GGPLDGTYR peptide (m/z 611.4— y-series ion, and m/z 
411.4—bicharged y-series ion) and of IS peptide (GGPLEGTYR; m/z 625.4—y-
series ion, and m/z 418.2—bicharged y-series ion) were chosen for MRM 
experiments. CA II-specific peptide and IS peptide retention times differed of less 
than 0.1 min. In Fig. 3, the masschromatogram relative to the sum of the selected 
transitions for each peptide, obtained by analyzing CA II in a human serum 
sample, is reported. 
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Fig. 3: Positive electrospray mass-chromatogram in multiple reaction monitoring 
mode relative to the sum of the selected transitions for carbonic anhydrase II-
specific peptide (GGPLDGTYR, m/z 468.4 → 411.4; 611.4) and IS 
(GGPLEGTYR, m/z 475.4 → 418.2; 625.4) 
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2.3.5 Method performances 
Calibration regression line and matrix effect evaluation 
Calibration graphs were constructed as described in ―Experimental‖ section. 
Three different regression line types were considered: (1) external calibration; (2) 
standard additions; (3) matrix-matched calibration. The standard addition 
regression lines were constructed taking into account both the absolute signal 
areas and the areas normalized for the IS response. Every dataset was obtained by 
triplicate measurements, interleaving three blank samples before the next series of 
injections. The results was evidenced the standard addition method was preferred 
to the matrix-matched calibration performed in pooled sample aliquots in order to 
obtain the matrix effect variability originated by non-homogeneity of serum 
sample. Most remarkably, the standard addition, the matrix matched, and the 
external calibration regression lines, after normalization by IS response, did not 
evidence significant differences in slope: mean bmatrix/bstandard was 0.95, and mean 
bstandard addition/bstandard was 0.93. 
 
Accuracy and precision 
Accuracy and precision were estimated from the analytical recovery calculated by 
adding known amounts of authentic CA II to the serum samples and the IS after 
tryptic digestion, as reported in the ―Experimental‖ section (third set of 
experiments). Precision was also measured as the between-day relative standard 
deviation (RSD, %) from spiked and unspiked samples analyzed six times. A 
mean recovery of 81±10% was obtained, and differences among the three spiked 
levels were not significant at p<0.05. By comparing these values with absolute 
recoveries reported above, it appears that the selected IS compensates for 
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incomplete peptide recoveries, whereas a correction for intact protein loss, likely 
from the digestion step, can be accomplished. Between-day precision for unspiked 
samples seems appropriate for the purpose of biomarker determination [52]. 
Reproducible tR, in association with m/z ratio, are important factors for 
characterizing a peptide sequence. For this reason, tR reproducibility for the 
HPLC-Chip-QqQMS/MS system was also tested. Target peptide tR was measured 
over 1 month obtaining an average value of 5.01±0.42 min. As can be seen, there 
is an excellent reproducibility usually not achieved by conventional 
nanoHPLC/nano-ESI configurations. 
 
Detection and quantification limits 
The instrumental limit of detection (LOD) was estimated by the MRM LC-
MS/MS chromatogram resulting from the analysis of 0.1 fmol of the synthetic CA 
II-specific peptide from a standard solution injected. The selected transitions from 
data set were extracted obtaining the resulting traces. Thereafter, the peak height-
to-averaged background noise ratio (S/N) was measured. The background noise 
estimate was based on the peak-to-peak baseline close to the analyte peak. For 
GGPLDGTYR peptide, a definition of LOD as the amount giving S/N=3 for the 
second most intense 
transition was adopted. Data are shown in Table 2, together with instrumental 
LOQ, estimated considering the sum of the two transition ion currents selected for 
the peptide and defining it as the amount giving S/N=10. Method identification 
limit (MIL) [78] and method quantification limit (MQL) were estimated in the 
same way of LOD and LOQ, respectively, by analyzing a physiological sample. 
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Tab.2 Method performances 
 
CA II quantitation in human serum samples 
External calibration and standard addition method were employed for CA II-
specific peptide quantification. The molar concentration of the peptide was 
assumed equal to the molar concentration of CA II. Recovery correction was 
applied. Eight human serum samples from apparently healthy subjects (five men 
and three women, aging 20–40) were analyzed, and for each sample, three RP-
HPLC runs were done. The CA II concentration in serum was estimated to be 56 
pmol/mL (RSD=21%) and 61 pmol/mL (RSD=24%) by using external calibration 
and standard addition, respectively. 
 
2.4 Conclusion 
The explosive growth in proteomic research for biomarker discovery, with its 
huge number of samples, demands high throughput, high sensitive, and high 
reproducible nano-LCMS technologies. In this work, we developed a method able 
in quantifying in serum CA II, a protein present at concentration level about five 
orders of magnitude lower than that of the most abundant proteins, by using nano-
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LCnano- ESI-MS/MS. The same scheme, based on the molar equivalence of a 
specific proteolytic peptide with the peptide-producing protein and a nonlabeled 
peptide as IS experimented for a protein present in cardiac tissue samples at 
concentration of about hundreds of picomoles per gram [70], can be used for a 
protein in serum at few picomoles per milliliter levels, providing that a suitable 
nanospray MS device is adopted. In addition, using a chromatographic 
purification step instead of a most abundant serum protein depletion kit, protein 
loss due to aspecific interactions with the proteins bonded by antibodies can be 
avoided. The hardware miniaturization introduced by Chip technology has 
radically reduced analysis time and cost and has increased efficiency and 
sensitivity. Moreover, using this device allows to reduce matrix effect; then it is 
possible to use the external calibration for quantification. 
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CHAPTER 3: Immunoprecipitation on magnetic beads and 
liquid chromatography–tandem mass spectrometry for carbonic 
anhydrase II quantification in human serum 
 
 
3.1 Introduction 
Most of the studies dealing with biomarker discovery on blood are focused on the 
cell leakage products potentially present in that matrix; indeed, increased serum 
levels of various proteins are routinely used for diagnostic purposes [79–82]. The 
analysis of serum is challenging because of the large dynamic range of protein 
concentrations, spanning more than 10 orders of magnitude [79,83]. In particular, 
the presence of high-abundance proteins such as albumin and immunoglobulins, 
whose concentrations represent 60–90% of the total serum protein content, 
enhances the difficulty of detecting the low-abundance proteins of interest [83]. 
Recently, a multisite assessment of the precision and reproducibility of multiple 
reaction monitoring (MRM)1-based measurements of target proteins in plasma 
demonstrated that this platform may be very reproducible for proteins present at 
moderate to high abundance (>2 mg/ml) in nondepleted, nonfractionated plasma 
[84]. On the contrary, the reduction of sample complexity is an essential first step 
in the analysis of the serum low-abundance proteins, and it is often achieved by 
high-abundance protein depletion [85]. A common approach is the affinity 
removal method using antibody- based resins (both monoclonal and polyclonal) or 
affinity dye-based resins [85–87]. There are several affinity removal columns or 
kits commercially available for depleting up to 20 major abundant serum proteins 
[87,88]. Although this strategy is highly specific, even after depletion the 
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remaining proteins are still sufficiently abundant to hamper the low-abundance 
protein determination. Moreover, some authors have recently pointed out the risk 
of losing low-abundance proteins and biomarkers when using affinity-based 
depletion due to the association of the targeted proteins with the abundant ones 
[83,87,89,90], but different results have also been published [90–93]. Another 
method of reducing serum sample complexity is the filtration through molecular 
weight cutoff membranes [87,89] for removing the high-molecular-weight 
proteins, including albumin. Solvent precipitation has also been employed, in 
particular for albumin depletion [87]; the method is nonspecific but presents the 
advantage of being rapid and cheap compared with the immunoaffinity- based 
methods. For isolation of the fraction containing the target proteins, liquid 
chromatographic and electrophoretic fractionation techniques have been used 
[87]. A promising approach is the employment of affinity reagents for specific 
enrichment or isolation of target proteins [83,94]. Recently, increasing attention 
has been given to the development and application of separation techniques 
employing small magnetic particles. Magnetic carriers bearing an immobilized 
affinity or hydrophobic ligand or ion exchange groups, or magnetic biopolymer 
particles having affinity to the isolated structure, are mixed with the sample 
containing the target compound [95]. Following an incubation period in which the 
target compound binds to the magnetic particles, the whole magnetic complex is 
easily and rapidly removed from the sample using an appropriate magnetic 
separator. The isolated target compoundcan then be eluted and used for 
downstream applications and detection methods. Several types of mass 
spectrometry (MS) techniques in conjunction with various liquid chromatography 
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(LC) separation methods are adopted for proteomic measurements. In particular, 
the MRM acquisition mode is the most employed one in targeted proteomics 
[79,83,96–98]. For absolute quantitative analysis, labeling and labelfree strategies 
[99] are currently carried out, both aiming to correlate the mass spectrometric 
signal of proteotypic peptide with the relative or absolute protein quantity directly 
[100]. Carbonic anhydrase II (CA II), a single polypeptide chain of 29 kDa 
molecular weight, is present in the cytosol of most tissues even if the highest 
concentration is found in erythrocytes. It catalyzes the hydration of CO2 and the 
hydrolysis of esters, and its deficiency has been associated with pathological 
consequences such as mental retardation and cerebral calcification, osteoporosis, 
and renal tubular acidosis [101,102] as well as Down syndrome [103,104] and 
Alzheimer‘s disease [104]. Although serum is not the natural site of CA II, in 
consequence of cell release, this protein could be present at low concentration in 
serum. Furthermore, because CA II is involved in serious diseases, it represents an 
interesting model to investigate the separation, identification, and quantification 
of proteins present in low concentration in complex matrices. In a recent study by 
our laboratory [105], CA II quantification in serum was performed by automated 
LC chip technology coupled with an electrospray ionization (ESI) source and a 
triple quadrupole mass spectrometer, operating in MRM acquisition mode, after 
purification by reversed phase LC, enzymatic digestion, and surrogate peptide 
selection. The highly sensitive nanoelectrospray chip technology was necessary 
because only 1 μL of serum could be submitted to the LC isolation step without 
column overloading. In the current study, a Protein G magnetic bead-based 
antibody platform amenable to high throughput is proposed for the selective 
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enrichment of CA II in human serum, followed by its accurate and reliable 
quantification by a label-free procedure performed on a less technologically 
sophisticated LC–ESI–tandem mass spectrometry (MS/MS) system. Magnetic 
beads bound to polyclonal anti-CA II antibodies as affinity probes to isolate the 
specific target protein, and a conventional LC–ESI–MS/MS apparatus amenable 
to small molecule quantitation, were used for the determination of the CA II 
proteotypic peptide produced through proteolysis. 
 
3.2 Experimental part 
3.2.1 Reagents and chemicals 
Anti-CA II polyclonal antibody was purchased from U.S. Biological 
(Swampscott, MA, USA), and Dynabeads Protein G were obtained from 
Invitrogen (Carlsbad, CA, USA). Synthetic peptide standards (5 mg each, certified 
title P95%), corresponding to GGPLDGTYR (CA II proteotypic peptide) and 
GGPLEGTYR (internal standard [IS]), were purchased from CRIBI Center 
(Padova University, Italy). The human CA II standard (<80%), dimethyl 
pimelimidate dihydrochloride (DMP), triethanolamine, Tween 20, Bradford 
reagent, ammonium bicarbonate, phosphate-buffered saline (PBS, pH 7.2), and 
trifluoroacetic acid (TFA) were obtained from Sigma–Aldrich (St. Louis, MO, 
USA). Tris (hydroxymethyl) aminomethane, 1,4-dithiothreitol (DTT), 
iodoacetamide (IAA), urea, and protease inhibitor mix were purchased from GE 
Healthcare (Uppsala, Sweden). All organic solvents were of the highest grade 
available from Carlo Erba Reagents (Milan, Italy) and were used without any 
further purification. Ultrapure water was produced from distilled water by a Milli-
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Q system (Millipore, Billerica, MA, USA). Modified porcine trypsin, sequencing 
grade, was commercialized by Promega (Madison, WI, USA). Peptide stock 
solutions were prepared in 0.1% TFA at 1 g L
-1
 and stored at -20 °C. The human 
CA II standard was reconstituted with 0.1% TFA at 1 g L
-1
 and stored at -80 °C. 
Its actual title was tested by the Bradford assay and was found to be 85 ± 5%. 
 
3.2.2 Samples 
Serum samples were obtained from the Department of Experimental Medicine at 
Sapienza University of Rome (Italy) by venipuncture of healthy volunteers (20–40 
years of age), with collection done in a BD P100 Blood Collection System 
(Becton Dickinson, Franklin Lakes, NJ, USA) with K2EDTA anticoagulant and 
protease inhibitors mix (GE Healthcare). After clot formation, the sample was 
centrifuged at 1000g for 15 min. The serum was removed, and aliquots were 
stored at -80 °C. All serum samples were checked to verify the absence of 
hemolysis.  
 
3.2.3 Immobilization of antibody on magnetic beads  
The antibody solution (400 μL of 1μg μL-1 anti-CA II) was added into an 
Eppendorf microcentrifuge tube containing 200 μL (6 mg) of prewashed 
Dynabeads Protein G and incubated by gentle mixing at room temperature (RT) 
for 2 h to allow time to attach onto the surface of the beads. Following incubation, 
residual unbound antibody was removed by washing two times with 0.5 ml of 
citrate phosphate buffer (pH 5.0) with 0.05% Tween 20. Approximately 10 μg of 
antibody was bound per milligram of beads. For crosslinking of antibody to beads, 
the Dynabeads Protein G with immobilized polyclonal antibody were washed with 
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1 ml of 0.2 mol L
-1
 triethanolamine (pH 8.2) and resuspended in 1 ml of freshly 
prepared cross-linking buffer (20 mmol L
-1
 DMP in 0.2 mol L
-1
 triethanolamine, 
pH 8.2). The mixture was incubated under gentle rotation for 30 min at RT and 
placed on a magnet, and then the supernatant was discarded. To stop the reaction, 
the beads were resuspended in 1 ml of 50 mmol L
-1
 Tris (pH 7.5) and incubated 
for 15 min, and then the beads were rinsed three times with 1 ml of 100 mmol L
-1
 
PBS with 0.05% Tween 20 before use. 
 
3.2.4 CA II capture and digestion 
To capture CA II, the Dynabeads Protein G with immobilized antibody were 
incubated at 4 °C for 1 h, under gentle mixing, with 20 μL of serum diluted with 
100 mM PBS (1:49, v/v), and then the beads were recovered from the sample and 
washed three times with 1 ml of 100 mmol L
-1
 PBS. Immunocomplex was 
resuspended in 40 μL of 6 mol L-1 urea solution in 25 mmol L-1 ammonium 
bicarbonate and 2 μL of 10 mmol L-1 DTT and incubated at 37 °C for 1 h, under 
slight agitation, to denature captured antigen. Then 8 μL of 10 mmol L-1 IAA was 
added, and the immunocomplex was incubated at RT for 1 h in the dark. 
Subsequently, 8 μL of 10 mmol L-1 DTT was added and incubated at 37 °C for 1 
h, under slight agitation, to consume any leftover alkylating agent and to avoid 
trypsin alkylation. The mixture was then diluted with 25 mmol L
-1
 ammonium 
bicarbonate to obtain a final urea concentration of 1 mol L
-1
. Reconstituted trypsin 
solution (20 μg ml-1 in 25 mmol L-1 ammonium bicarbonate) was added to a final 
concentration of 5.8 μg ml-1. The samples were allowed to digest under gentle 
mixing overnight at 37 °C, the digestion was quenched by adding 4 μL of formic 
acid, and then 50 μL of 3 pg ml-1 IS solution 
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was added. The supernatant (~400 μL) containing the peptides coming from both 
antigen and antibody digestion was recoveredù using a magnet, and an aliquot 
was subjected to LC–MS/MS analysis. 
 
3.2.5 Chromatographic and mass spectrometric conditions 
The LC apparatus consisted of a series 200 binary LC micropump, a series 200 
binary LC pump, two vacuum degassers, an autosampler (PerkinElmer, Norwalk, 
CT, USA), and an eight-port Valco valve equipped with a 100 μL peek loop 
(VICI AG International, Schenkon, Switzerland). The LC separation was carried 
out on a Jupiter Proteo 4 μm C12 column (150 x 1 mm i.d., 4 μm average particle 
size, 90 Å pore size) equipped with a 2.1-mm i.d. guard column from 
Phenomenex (Torrance, CA, USA). A C18 trap column (4.0 x 2.0 mm i.d.) 
supplied by Phenomenex was used for on-line solid phase extraction (SPE) with 
100 μL of samples being injected. ESI–MS was carried out on an API 3000 triple 
quadrupole instrument equipped with a TurboIonSpray (TISP) interface and with 
a built-in software-controlled eight-port valve (Applied Biosystems/MDS Sciex, 
Concord, ON, Canada). The LC–MS system, data acquisition, and processing 
were managed by Analyst software (version 1.4.2, Applied Biosystems/MDS 
Sciex). The scheme of the on-line system is shown in Fig. 4. The two alternate 
positions of the software-controlled eight-port valve allowed flows witching in the 
trap column. The LC binary pump (pump 1) was used to deliver a 300 μL/min 
flow rate through the trap column for loading and washing the injected sample, 
whereas the LC binary micropump (pump 2) was used to deliver a 70 μL/min 
flow rate for eluting the analyte from the trap column in back flushing mode, for 
carrying out the chromatographic run, and subsequently for flushing and 
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equilibrating the column. The mobile phases used for sample loading and washing 
(pump 1) were water (A) and acetonitrile (B), with both containing 1% (v/v) 
formic acid. Mobile phases for analyte elution (pump 2) consisted of water (C) 
and acetonitrile/ methanol (60:40, v/v) (D), with both containing 0.1% (v/v) 
formic acid. The sample was loaded onto the trap column and desalted by washing 
with 2% B for 2 min. Elution was performed by switching the eight-port valve; 
after an isocratic step at 10% D for 1 min, D was linearly increased to 40% within 
7 min and then the eight-port valve was resettled to the starting position and B and 
D were brought to 95% within 1 min and held constant for 4 min to rinse the 
column and trap column. Finally, the D content was lowered to 10% and the B 
content was lowered to 2% over 1 min, and both the column and trap column were 
reequilibrated for 15 min. The mass spectrometer was calibrated using 
polypropylene glycol as standard (Applied Biosystems). Ionization and mass 
spectrometric conditions were optimized for both of the peptides (CA II-specific 
peptide and IS peptide) by infusing at a 5 μL min-1 flow rate a 0.1 ng μL -1 
solution prepared in water/acetonitrile/formic acid (70:30:0.1, v/v/v). TISP 
interface was operated in the positive ionization mode by applying to the capillary 
a voltage of 5500 V. Nitrogen was used as curtain, nebulizing, and turbo spray 
gases (heated at 300 °C), and the gas pressures were set at 20, 30, and 40 psi, 
respectively. Nitrogen, kept at medium pressure (arbitrary units), also served as 
collision gas. Diprotonated molecules ([M + 2H]
2+
) were mass selected by the first 
quadrupole and fragmented. In the product ion scan mode, the range of m/z 200–
1000 was monitored for both CA II proteotypic peptide and IS. 
A flow chart of the analytical procedure is shown in Fig. 5. 
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Fig. 4: On-line LC–MS/MS CA II proteotypic peptide analysis after off-line 
immunoextraction and tryptic digestion. Analytical system scheme: 1, position 
used for sample loading, extraction, analytical column equilibration, and cartridge 
regeneration; 0, position used for peptide elution from the extraction/enrichment 
trap column and peptide separation by the analytical column. Mobile phases: A, 
water; B, acetonitrile (containing 1% [v/v] HCOOH); C, water; D, 
acetonitrile/methanol (60:40, v/v, both containing 0.1% [v/v] HCOOH). a, pump 
1; b, pump 2; c, autosampler; d, 100 μL loop; e, eight-port valve; f, 
extraction/concentration trap column; g, analytical column; h, mass spectrometer; 
w, waste. 
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Fig. 5: Flow chart of the analytical procedure. 
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3.2.6 Calibration and recovery studies 
Standard solutions for calibration were prepared by drawing the appropriate 
volume of the CA II-specific peptide GGPLDGTYR working standard solution so 
as to obtain nine concentration levels in the range of 0.05–100 pg μL-1 and 50 μL 
of a 3 pg μL-1 IS peptide GGPLEGTYR working standard solution. The solvent 
was evaporated at 37 °C under a gentle N2 stream, and then the solution was 
reconstituted with 400 μL of 25 mmol L-1 ammonium bicarbonate acidified with 
formic acid (25 mmol L
-1
). Volumes of 100 μL were injected. The ion current 
profiles of the selected transition pairs for the two peptides were extracted from 
the LC MRM dataset, the resulting peak areas were measured, and the plot of the 
ratio between the peak areas of the CA II synthetic peptide and the IS peptide 
versus concentration was obtained. The matrix- matched calibration line was also 
constructed by using a serum pool obtained by mixing serum aliquots from the 
eight healthy subjects. Nine 20 μL aliquots were processed as reported above. 
Next, to obtain the same concentrations as for the external calibration, the samples 
were transferred into vials spiked with the 
suitable volume of standard and IS solutions after solvent evaporation. All 
samples were run in triplicate interleaving three blank samples before the next 
series of injections, and results were averaged. From the initial set of candidates, 
two suitable transition pairs were chosen for acquisition in MRM mode for both 
peptides. The declustering, entrance, and focusing potentials were maintained at 
the optimal values of 28, 7, and 370 V, respectively, whereas collision energy was 
optimized for each ion. The LC–ESI–MS/MS parameters are summarized in 
Table 3. Recovery studies were conducted by spiking human serum samples with 
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different amounts of CA II standard at different procedure steps while maintaining 
the IS amount constant. 
 
Peptide 
Retention 
time 
(min) 
Precursor 
ion 
MRM 
transition 
Relative 
abundance (%) 
GGPLDGTYR 
(CA II marker) 
4.2 [M + 2H]
2+
 
468.3→496.3 100 
468.3→411.2 30 
GGPLEGTYR 
(Internal standard) 
4.0 [M + 2H]
2+
 
475.3→625.3 100 
475.3→418.2 90 
 
Tab.3: Instrumental parameter settings under MRM conditions for the two 
peptides: CA II proteotypic peptide and IS peptide. 
 
 
3.3 Results and discussion 
3.3.1 Abundant protein depletion 
To avoid significant interference due to nonspecific interaction of the most 
abundant serum proteins with the antibody capture of CA II, in a first attempt, 
immunoaffinity depletion of serum samples was carried out as the first analytical 
step before immunoprecipitation. Depletion was performed on the Agilent Human 
14 Multiple Affinity Removal System (MARS) immunoaffinity spin cartridge 
according to the recommendations of the manufacturer. After depletion, the 
sample was handled as described in Materials and methods. Although recoveries 
from spiked samples were 80–90%, quantitative determinations on unspiked 
individual serum samples gave both lower concentrations and lower between-
sample standard deviations (16.3 pmol ml
-1
 and relative standard deviation [RSD] 
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= 18%, respectively, n = 8) compared with the previous results obtained in our 
laboratory [27]. This result suggested that serum depletion may lead to loss of CA 
II to an unpredictable extent. Probably, the CA II is concomitantly removed 
during depletion due to the nonspecific binding to depleted proteins [106]. Thus, 
immunoprecipitation of CA II was optimized on whole serum. 
 
3.3.2 Development of magnetic separation technique 
Among the different commercially available magnetic bead systems tested, 
characterized by a variety of surface chemistries, the Dynabeads Protein G were 
chosen for the CA II antigen capture procedure. Indeed, this magnetic bead 
system showed high antibody coupling efficiency, good functional orientation of 
antibody for antigen capture, low background binding of serum peptides and 
proteins, and appropriate specificity for the succeeding MS analysis. During 
method development, each step was optimized to maximize the final recovery of 
CA II. An increasing amount of anti-CA II polyclonal antibody (25, 50, 100, and 
150 μg) was incubated with a fixed amount of Dynabeads Protein G (50 μL, 
corresponding to 1.5 mg of beads) in a fixed sample volume of 100 μL, keeping 
the incubation time constant (5 h). An estimate of the antibody amount bound to 
Protein G magnetic beads was performed by comparing protein concentrations 
measured by Bradford assay by using an immunoglobulin G (IgG) standard. The 
supernatants containing the unbound antibody were discarded, and the complex 
was washed twice with the washing buffer to remove unbound antibody. Then the 
antibody was recovered after complex dissociation with citrate buffer (pH 2.5), 
and its concentration was determined spectrophotometrically. The bonded amount 
of anti-CA II polyclonal antibody increased up to 14.9 ± 0.5 μg for 50 μL of bead 
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solution using 100 μg of antibody. This ratio (6.7 μg antibody/mg beads) is very 
similar to that reported by Berna and coworkers [107] for a different antibody (8 
μg antibody/mg beads). Next, keeping constant the amount of anti-CA II 
polyclonal antibody (100 μg) and the amount of Dynabeads Protein G (50 μL), the 
efficiency of the Dynabeads Protein G/anti-CA II polyclonal antibody binding 
reaction was tested by increasing the incubation time (1 h, 2 h, 4 h, 8 h, and 
overnight). No significant increase in the binding reaction was observed from 2 h 
to overnight incubation times. The effect of cross-linking between Dynabeads 
Protein G and anti-CA II polyclonal antibody was also investigated. In all cases in 
which the anti-CA II polyclonal antibody was covalently bound to the magnetic 
beads by a cross-linking reaction, the LC–MS/MS analysis of the peptide at m/z 
468.2 ([M + 2H]
2+
) exhibited a significant peak area increase (>30%). Probably, 
when cross-linking was not performed, a fraction of the immunocomplex was lost 
during washing. After the best conditions for obtaining the complex antibody 
beads had been determined, we optimized the incubation volume and the 
incubation time for serum samples. The same amount of magnetic beads with 
immobilized antibody (200 μL) was used for extracting 20 μL of serum spiked 
with 0.5 pmol of CA II standard and diluted in different volumes (200, 500, 750, 
and 1000 μL) of PBS. The samples were incubated overnight at 4 °C. The best 
LC–MS/MS result in terms of recovery was obtained using 20 μL of serum 
diluted to 500 μL with PBS buffer. Moreover, the effect of sample incubation time 
was investigated (30 min, 1 h, 2 h, 4 h, 8 h, and overnight) using 20 μL of diluted 
serum. Recovery did not further increase after 1 h of incubation, whereas for 
higher incubation times an increase of background signal in the MRM mass 
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chromatogram was noted, probably due to the extraction of other proteins by 
means of nonspecific interactions. 
 
3.3.3 Digestion efficiency 
The enzymatic digestion protocol was optimized to obtain the best peptide 
formation yield. For this purpose, the digestion efficiency was checked by spiking 
immunocomplex sample after immunoprecipitation with a known amount of CA 
II standard (2 nmol) while maintaining a constant volume (400 μL), and the 
recovery of surrogate peptide by increasing the trypsin concentration was 
evaluated by LC–MS/MS. Experiments were done in quadruplicate, and the 
results are reported in Tab. 4. A recovery of 97 ± 3% was obtained by adding to 
approximately 250 μL of sample 100 μL of a trypsin solution (20 ng μL-1), 
suggesting that in these conditions the proteotypic peptide released from CA II 
digestion could stoichiometrically represent the absolute amount of its parent 
protein in serum. This concentration of enzyme is higher than that usually adopted 
in other protocols, including those adopted by our laboratory in a previous study 
[105,107]. 
 
 
Tab. 4: Hydrolysis yield. 
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3.3.4 Method validation 
To determine the performance characteristics of the magnetic beads-based capture 
system coupled to LC–ESI–MS/MS analysis, we assessed linear range, method 
detection limit (MDL), method quantification limit (MQL), recovery, accuracy, 
and precision. In addition to ionization efficiency and reproducibility, the selected 
proteotypic peptides also need to meet the proteotypic selection criteria described 
in literature [108,109]. In our previous work based on protein isolation by reverse 
phase high-performance liquid chromatography (RP–HPLC) before protein 
digestion, the peptide GGPLDGTYR was selected as an appropriate peptide of 
CA II and the peptide GGPLEGTYR, having very similar chemical and physical 
properties, was selected as the relative IS. The benefits and limits of a nonlabeled 
peptide as IS have been discussed previously [110]. For this reason, they were 
also the first candidates for this method. From the product ion MS/MS spectrum 
of diprotonated GGPLDGTYR peptide at m/z 468.3 (shown in Fig. 6) and 
diprotonated GGPLEGTYR at m/z 475.3, the two most intense transitions were 
chosen for MRM acquisition. The supernatant containing the tryptic cleaved 
peptide mixture was separated from magnetic beads, and an aliquot was injected 
into the LC–ESI–MS/MS system. The mass chromatograms relevant to the two 
selected transitions for CA II-specific peptide are shown in Fig. 7 A and B, and 
we see that background compounds present in the sample give, for the transition 
468.3→212.3 (Fig. 7A), a signal poorly resolved from that relevant to the 
proteotypic peptide. This problem was solved by changing the selected transition 
468.3→212.3 to 468.3→496.3 (Fig. 7C) that did not show background peaks. The 
IS was eluted approximately 0.2 min earlier and did not show any background 
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interference. Peptide adsorption is an important factor that may affect accuracy 
and reproducibility. To reduce peptide adsorptive processes, protein low-retention 
tubes were used. Surface adsorption phenomena are ruled by the adsorption 
constant, so the adsorbed compound amount decreases as the solvent volume 
increases. In addition, salt removal by means of C18 mini-columns is a 
timeconsuming critical step in the peptide analysis protocols. Bearing in mind 
these considerations, we devised an on-line injection system that permitted us to 
inject by an autosampler a relatively large volume (100 μL) into a small bore (1 
mm i.d.) column. Our system is more complicated than that previously used for a 
similar study [107], but the current system has some advantages: (i) the injection 
and trap washing with water can be made during analytical column equilibration, 
(ii) highly retained compounds did not enter  the analytical column, and (iii) the 
trap washing with strong solvent can be made during sample separation. 
Calibration graphs were constructed as described in Materials and methods. Two 
different regression lines were considered: external calibration and matrix-
matched calibration. When the areas of the standard peaks were not normalized 
for the IS response, the ratio between the slopes (bmm/bext) was 0.73 ± 0.6, whereas 
after normalization it was 1.04 ± 0.05. These data showed that ion suppression 
due to matrix compounds is moderate but not negligible and that the unlabeled IS 
was adequate. The memory effect was nearly 100% when the most diluted 
standard solution (0.05 pg μL-1) was injected after the most concentrated one (100 
pg μL-1) and became negligible only after three blank injections. The response 
was found to be linear for the calibration range used, with R2 = 0.9990 and 0.9863 
for the external and matrixmatched calibrations, respectively. Recovery, accuracy, 
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and reproducibility of the method were calculated by analyzing six aliquots of a 
serum pool unspiked and spiked with CA II at three concentration levels during 3 
weeks, with three LC–MS/MS analyses being performed for each 
immunoprecipitated sample. Results are shown in Table 5. If we consider that the 
tryptic digestion regarding the representative peptide recovery is quantitative, the 
roughly 23% analyte loss should be due to an incomplete capture by the antibody. 
The RSD (<12%) was comparable to the RSDs of similar studies [107,111,112]. 
Instrumental limit of detection (LOD), calculated as three times the intercept of 
the external calibration regression line, was 2 pg of the injected synthetic peptide 
(~2 fmol). The method identification limit (MIL) and method quantification limit 
(MQL) were estimated from the serum samples, with samples being run in 
triplicate and results being averaged. MIL (signal/noise [S/N] = 3 for the second 
most intense transition in MRM) and MQL (S/N = 10 for the sum of the two 
selected transitions), expressed as pmol ml
-1
 CA II in serum, were 0.3 and 0.5, 
respectively. Although the performances of the method based on 
immunoprecipitation by magnetic beads were not superior to those based on 
reversed phase LC fractionation, it present two advantages: (i) many samples can 
be treated contemporaneously and (ii) due to the higher selectivity and loadability, 
a less sophisticated MS/MS platform can be used. 
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Fig.6: Product ion spectrum of the diprotonated molecule of CA II specific 
peptide GGPLDGTYR (m/z 468.3) acquired at 24% relative collision energy, 
obtained by analyzing a 10 pg μL-1 standard solution in infusion mode, at a 5 μL 
min
-1
 flow rate. 
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Fig. 7: LC–ESI–MS/MS extracted ion current in MRM mode deriving from the 
analysis of an unspiked sample relative to 468.3→212.3 transition (A), 
468.3→411.2 transition (B), and 468.3→496.3 transition (C). 
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Tab. 5:  Method recoveries and precision. 
 
 
3.3.5 CA II quantitation in human serum samples 
Eight human serum samples from apparently healthy subjects (seven males and 
one female, 20–40 years of age) were analyzed, and for each sample three RP–
HPLC runs were done. For CA II-specific peptide quantification, external 
calibration was employed and recovery correction was done. The concentration of 
the endogenous CA II in serum was found to be 27.3 pmol ml
-1
 (RSD = 65%). 
Both the mean concentration and RSD were very different from those found in a 
previous study by our laboratory (56 pmol ml
-1
 and 21%, respectively). Because 
both methods were validated in a similar way and the sampled population was 
different but similar, a possible explanation may be that the external addition of 
standard CA II was not similar to the endogenous CA II situation at the isolation 
step in both cases. The chromatographic isolation used in the previous work 
fractionated denaturated samples, whereas the immunologic capture is performed 
in native samples. If the protein were present in different forms (modified or 
associated in complex structures), the affinity for the antibody would be different, 
so the recovery of the standard may give erroneous indications. 
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3.4 Conclusions 
As demonstrated by the first attempts to conduct a multilaboratory assessment of 
the precision and reproducibility of MRM-based measurements of proteins in 
plasma published recently [84,113], the preclinical validation of candidate 
biomarker by LC–MS/MS is becoming a hot topic. In the method described in this 
work, the protein of interest, CA II, was isolated from serum by 
immunoprecipitation. A proteotypic peptide, produced stoichiometrically through 
proteolysis with trypsin, was ultimately quantified, using a synthetic peptide and a 
structural analogue free-labeled synthetic peptide as IS, by LC– ESI–MS/MS in 
MRM acquisition mode. An analytical column having 1 mm internal diameter and 
a triple quadrupole instrument were employed. A column switching system was 
used for on-line SPE sample cleanup. The assay was validated by recovery studies 
of both intact proteins and proteotypic peptide. Good precision and MDL as low 
as 0.5 pmol ml
-1
 were obtained. This strategy, based on isolation of target protein 
by immunoaffinity and its absolute quantification by quantifying one of its 
proteotypic products, could represent a very specific and sensitive analytical 
approach to reach the analytical goal of low-abundance protein determination in 
clinical samples such as serum. Nevertheless, a comparison of physiological CA 
II concentrations in sera of eight apparently healthy subjects obtained by using 
this approach with those found in a previous study by using chromatographic 
isolation of the fraction containing the target protein followed by a more 
technologically advanced platform, such as chip LC–MS/MS [109], showed very 
different values. If our data are not affected by an unrecognized error, these results 
pose a question. A protein may be present in a certain biological specimen in 
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different forms (e.g., free and involved in a complex with other molecules). Is the 
analysis of spiked samples ever a correct way for making validation? When trying 
to isolate the target from the most abundant proteins, what form is enriched? 
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CHAPTER 4: Evaluation of different two-dimensional 
chromatographic techniques for proteomic analysis of mouse 
cardiac tissue 
 
 
4.1 Introduction 
The general strategy in proteomic research includes sample preparation, protein or 
peptide separation, their identification, and data interpretation. Sample preparation 
is the first critical step that affects the outcome of the entire proteomic analysis. 
The next step is protein or peptide separation. The protein-level and peptide-level 
separations have relative advantages and disadvantages. Proteins are sensitive to 
precipitation upon exposure to high salt concentrations, to basic pH values, and 
organic solvents. Peptides, on the other hand, are relatively stable in solution and 
generally do not exhibit solubility issues. However, peptide-level separations also 
have limitations, including the scattering of tryptic peptides from a single parent 
protein into multiple fractions, which can potentially reduce protein identification 
scores. Furthermore for adequate representation of the proteome, only 
multidimensional separation techniques can provide resolving capability of 
thousands of protein species and have proven to be superior to one-dimensional 
approaches. Until recently, two dimensional gel electrophoresis (2-DE) was the 
technique most often used for protein separation. The limitations of 2-DE in 
detecting low abundance proteins, very small or large proteins, as well as basic 
and membrane/hydrophobic proteins [114-116], as well as difficulties with 
automation of the process, have forced researchers to look for other methods of 
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protein separation, such as multidimensional liquid chromatography coupled to 
mass spectrometry (MDLC-MS) or tandem mass spectrometry (MDLC-MS/MS).  
These techniques have emerged as a powerful tool for the large-scale analysis of 
such complex samples. [117-120]. MDLC combines two or more forms of LC to 
increase the peak capacity, and thus the resolving power of separation, to better 
fractionate peptides prior to entering into the mass spectrometer. It better resolves 
peptides differing in charge and hydrophobicity to minimize ion suppression and 
improve ionization efficiency, and it simplifies the complexity of peptide ions 
entering into the mass spectrometer to minimize undersampling. This last aspect is 
important because the tandem MS process is driven by data-dependent data 
acquisition and has a finite cycle time. A higher peak capacity and better resolving 
power improve the acquisition of data and can lead to a better representation of 
the proteins in the mixture and permit the identification of low-abundance 
proteins [117,120-122]. Various orthogonal prefractionation techniques on the 
protein and peptide level have been utilized for the characterization of a part of 
the yeast proteome leading to the identification of thousands of proteins [123-
125]. A variety of separation modes have been employed to achieve protein-level 
separation, including size exclusion chromatography, [126,127] ion exchange 
chromatography, [128,129] isoelectric focusing (IEF), [130-134] gel separation 
(SDS-PAGE), [135,136] and reversed-phase chromatography (RP) [137-144]. In 
contrast to a protein-level separation followed by a peptide separation, a two-
dimensional peptide-level separation can be performed by employing two or more 
methods with different separation selectivities. A number of separation modes 
have been implemented to this end, including strong cation exchange (SCX), 
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[124,145-149] IEF, [150,151] capillary electrophoresis, [152,153] capillary 
isoelectric focusing (CIEF), [154,155] and mixed-mode pH reversed phase (RP-
RP) [156-159].  
Development of better method that leads to the greatest number of identified 
proteins has great scientific importance, in fact a full understanding of the 
molecular mechanisms involved in health and disease progression will require the 
identification of all forms of each protein involved in cellular processes.  
In health study the proteomic approach has proved to be particularly interesting 
for cardiovascular diseases and thereby improving our understanding of the 
mechanisms involved and identifying new biochemical factors and biomarkers 
associated in these diseases. 
Heart disease infact is the leading cause of mortality in industrialized countries 
and the development of novel therapeutic strategies is largely dependent on our 
understanding of the molecular basis of cardiac function and dysfunction [160]. 
With the availability of animal models mimicking human disease and expression 
profiling to detect changes in gene expression has been made considerable 
progress toward understanding the molecular basis of contraction, sarcomere 
assembly, regulation of muscle gene expression, and metabolism. The current 
focus on RNA in expression profiling has generated extensive datasets relating to 
cardiac and skeletal muscle disease, but protein expression and post-translational 
modifications (PTM) determine cardiac function too. Thus, the molecular analysis 
of heart disease would greatly benefit from a proteomics approach that combines 
the advantages of high throughput analysis (as in expression profiling) and the 
focus on protein levels and modifications. Accordingly, proteomics has now been 
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applied to investigate the molecular basis of cardiovascular and muscle disease, 
such as cardiac hypertrophy, atrophy, and ischemia [161-164]. 
The goal of  this work is to develop an appropriate method to study the proteome 
of cardiac system hence differential study of heart disease. To achieve this goal 
have been systematically compared the following chromatographic techniques: 
offline SCX combined with RP, mixed-mode pH RP-RP for peptide-level 
separation, and RP with two different columns for protein-level separation. We 
have also compared the following identification parameters: total proteins 
identified, total number of peptides identified (including redundant 
identifications), total number of unique peptides (only nonredundant 
identifications), average protein sequence coverage, and protein E-value 
(probability score). 
 
4.2 Experimental 
 
4.2.1 Reagents and chemicals 
Tris(2-carboxyethyl)phosphine hydrochloride (TCEP), protease inhibitor cocktail 
for mammalian tissue, ethylenediaminetetraacetic acid (EDTA), sodium vanadate, 
sodium fluoride, Bradford reagent (Bio-Rad Protein Assay Reagent, Bio-Rad, 
Hercules, CA, USA), trifluoroacetic acid (TFA), formic acid (FA) and trypsin 
from porcine pancreas were obtained from Sigma-Aldrich (St. Louis, MO, USA). 
Tris(hydroxymethyl)aminomethane (Tris), 1,4-dithiothreitol (DTT), 
iodoacetamide (IAA), and urea were purchased from GE Healthcare Amersham 
Biosciences (Uppsala, Sweden). 
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Methanol and acetonitrile ‗Plus‘ (ACN) of HPLC grade were obtained from Carlo 
Erba (Milano, Italy). All other solvents and chemicals were of analytical grade 
(Carlo Erba) and were used as supplied. Deionized water was further purified 
using a Milli-Q apparatus (Millipore, Bedford, MA, USA). 
 
4.2.2 Samples 
Mice (Mus musculus) employed in the experiment were 24-week-old C57blk 
healthy males from the Department of Histology and Medical Embryology of 
―Sapienza‖ Università of Rome (Italy). Mice were sacrificed and hearts were 
dissected and snap-frozen in liquid nitrogen. The tissue was stored in a freezer at 
–80°C until use. 
All procedures were carried out in compliance with the Italian Legislative Decree 
116/1992 in application of the EU Directive 86/609/EEC26 concerning the use of 
experimental animals. 
 
4.2.3 Protein extraction 
Protein extraction was carried out according to Nerenova et al. [165] with some 
modification. 
Heart tissues ground under liquid nitrogen were homogenized for 1 min using a 
little pestle. Then the sample was mixed with a buffer solution consisting of  20 
mmol L
-1
 Tris (pH 6.8), 0.2 mmol L
-1 
sodium vanadate, 50 mmol L
-1
 sodium 
fluoride, 2 mmol L
-1
 EDTA, 1% (v/v) protease inhibitor mixture. The better ratio 
of wet tissue weight : buffer solution volume (whole tissue homogenate) was 1: 4. 
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The suspension was centrifuged at 4 °C at 18000 x g for 20 min. After 
centrifugation, the supernatant was collected and the pellet was re-extracted with 
the same buffer. The procedure was repeated and the supernatant was combined to 
the first (neutral extract).  
The remaining pellet was extracted by mixing with a acid buffer of 15 mmol L
-1
 
aqueous TFA and 1 mmol L
-1
 TCEP (initial tissue weight : buffer volume = 1:4). 
The suspension was centrifuged at  4 °C at 18000 x g for 20 min. After 
centrifugation, the supernatant was collected and the pellet was re-extracted with 
the same buffer. The procedure was repeated and the supernatant was combined to 
the first (acid extract). Extracts were stored at –80 °C. Total protein concentration 
in each sample was determined by Bradford assay. 
 
4.2.4 Protein digestion 
After extraction, solvent was removed by vacuum centrifugation. The protein 
were redissolved with 100 µL of 100 mmol L
−1
 Tris (pH=7.8), and 6 mol L
−1
 urea 
solution. 
Cysteinyl disulfides were reduced with 200 mmol L
−1
 DTT for 30 min at 37 °C. 
Reduced disulfides were then alkylated with 200 mmol L
−1
 IAA for 30 min in the 
dark. Trypsin was added at a 1:8 enzyme-substrate (w/w) ratio and incubated for 
12 h at 37 °C. The digestion was quenched by adding 1% (v/v) TFA. 
 
4.2.5 Offline Strong Cation Exchange Chromatography (Off-SCX) 
100 μg sample of protein digest was vacuum-centrifuged to dryness and 
reconstituted in 100 μL of 75% (v/v) H2O, 25% (v/v) ACN, 5 mmol L
-1
 K2HPO4 
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at pH 3 (HPLC buffer A). A Rainin Dynamax HPLC equipped with a 100 μL 
sample loop, binary pump, UV detector, and fraction collector was used to deliver 
the reconstituted digest to a PolySulfoethyl A SCX column (2.1 × 250 mm, 5 μm, 
300 Å) from PolyLC (Columbia, MD). 
Peptides were eluted with a linear gradient of 75% (v/v) H2O, 25% (v/v) ACN, 
500 mmol L
-1
 K2HPO4 at pH 3 (HPLC buffer B) from 5 to 100% over 60 min. 
Fractions were collected every 5 min for a total of 12 fractions. 
Each fraction was vacuum-centrifuged to dryness and reconstituted in 20 μL of 
0.1% (v/v) FA; 2 μL of each reconstituted fraction was analyzed by LC-MS/MS 
(see below for details). 
 
4.2.6 Offline High-pH Reversed-Phase Chromatography (pH-RP) 
100 μg sample of protein digest was vacuum-centrifuged to dryness and 
reconstituted in 100 μL of 200 mmol L-1 ammonium formate at pH 10 (HPLC 
buffer A). A Rainin HPLC (see Off-SCX for description) was used to deliver the 
reconstituted digest to a Gemini C18 RP column (2 × 150 mm, 3 μm, 110 Å) from 
Phenomenex (Torrance, CA). Peptides were eluted with a linear gradient of 100% 
ACN (HPLC buffer B) from 5 to 35% over 60 min. Fractions were collected 
every 5 min for a total of 12 fractions. Each fraction was vacuum centrifuged to 
dryness and reconstituted in 20 μL of 0.1% FA (v/v); 2 μL of each reconstituted 
fraction was analyzed by LC-MS/MS (see below for details). 
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4.2.7 Offline C8 Protein Reverse Phase (C8-RP Prot) 
A 40 μg sample of undigested protein extract in 100 μL of water was delivered to 
a Zorbax 300SB-C8 column (150 mm × 4.6 mm i.d., 300 Å pore size, 5 µm 
particle size) from Agilent Technology (Santa Clara, CA, USA) with a 
securityguard ODS, 4 mm × 3 mm i.d. precolumn, supplied by Phenomenex 
(Torrance, CA, USA). To increase recovery and decrease protein adsorption, the 
column was heated to 60 °C. Compounds were separated using a gradient of ACN 
0.08% (v/v) TFA (B) and water 0.1% (v/v) TFA (A). The gradient, at a flow rate 
of 0.5 mL min
−1
, started with 15% eluent B and was linearly increased to 55% in 
55 min. The eluted proteins were monitored at 215 nm by UV detection. Fractions 
were collected every 5 min for a total of 12 fractions. Each fraction was vacuum-
centrifuged to ~50 μL, diluted to 100 µL of a solution 200 mmol L−1 Tris 
(pH=7.8), and 12 mol L
−1
 urea and digested according to the solvent-assisted 
protein digestion procedure. Each digested fraction was vacuum centrifuged to 
dryness. The digested fractions were reconstituted in 20 μL of 0.1% FA; 2 μL of 
each reconstituted fraction was analyzed by LC-MS/MS. 
 
4.2.8 Offline High Recovery Protein Reverse Phase (hr-RP Prot) 
The procedure for hr-RP Prot was followed exactly as well as C8-RP Prot except 
for different chromatographic column was used. Agilent (Santa Clara, CA) 
macroporous mRP-C18 column (4.6 × 50 mm, 5 μm) heated to 80 °C was 
employed instead of the C8 column from Agilent Technology. 
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4.2.9 LC/Chip-MS/MS 
Liquid chromatography was performed using an Agilent series 1200 instrument 
(Agilent Technologies, Waldbronn, Germany) consisting in 1200 Series 
nanopump with degasser; 1200 Series capillary pump; 1200 Series thermostatted 
microwell-plate autosampler, and HPLC-Chip/MS interface. 
Reverse phase nanoLC separation was performed on a μ-fluidic HPLC chip cube 
system (C18 reversed phase column, 300 Å pore size, 5 μm particle size, 75 μm 
i.d., 43 mm length) interfaced to a Q-ToF MS instrument (Agilent Technologies, 
Santa Clara, CA). 
Separation was performed at 300 nL min
-1
 flow rate using a 50 min gradient from 
5 to 45% B (eluent A, 95% (v/v) H2O, 5% (v/v) ACN, 0.1% (v/v) FA and eluent 
B, 95% (v/v) ACN, 5% (v/v) H2O,  0.1% (v/v) FA). Enrichment of the analytes 
prior to gradient start was performed by capillary pump running at 4 μL min-1 0% 
B (v/v). 
The analyses were performed in positive ionization mode with a capillary voltage 
set at 1,750 V and a delta electro multiplier voltage of 500 V. The drying gas flow 
was 4 L min
-1
 of nitrogen, and the drying gas temperature was 350°C. Because the 
HPLC-Chip interface uses an enclosed source, to achieve low background 
conditions, an additional 1.5 L min
-1
 of filtered air was added to the drying gas. 
The position of the nano-ESI Chip tip was optimized to produce a good direct ESI 
spray under the correct voltage and so to achieve high MS sensitivity and a stable 
spray. 
To maintain the mass accuracy, a short regular full mass range scan is performed 
in MS mode without filtering. Acquisition cycles were set as follows: first 
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acquisition was run in regular MS mode, second acquisition was run in special 
mode with a cutoff value at m/z 300 and no collision energy followed by a third 
(or more) acquisition in special mode with a m/z cutoff value of 300 and a low 
collision energy. Acquisition time for MS and special mode scans was set to 65 
ms and to 1 s, respectively. 
 
4.2.10 Database Search 
Agilent Mass Hunter was used to convert the files into .xml text files for database 
searching. Peptide masses were used to search the Swiss-Prot database using 
Mascot. The following parameters were used for both search engines: taxonomy 
was limited to Mus musculus (House Mouse), parent mass tolerance was 5 ppm, 
fragment mass tolerance was 0.4 Da, a maximum of one missed cleavages was 
allowed, carbamidomethylation was set as a fixed modification and oxidation was 
set as a variable modification. For the Mascot search results, the significance 
threshold was set at p < 0.05 (indicates identity or extensive sequence 
similarities).  
 
4.3 Results and Discussion 
4.3.1 Phase extraction 
Traditional methods of extraction are based on the use of detergents to break the 
cell membranes. 
The high concentrations of detergent are needed to break down the structure of 
sarcomeres and completely dissolving sarcomeric proteins but they are 
incompatible with most of chromatographic separation techniques. 
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The extraction procedure used in this work is simple, fast and does not require use 
of detergents. 
It has been optimized the ratio between buffer volume and weight tissue. 
Goodness of extraction has been so verified by the Bradford assay and the best 
ratio was found to be of 4mL of buffer extracting per gram of tissue (Tab. 6). 
 
 
Weight tissue:buffer volume 
ratio 
Extracted protein (µg) 
1:1 1.50 
1:2 2.05 
1:4 3.83 
1:8 2.90 
 
Tab. 6: Amount of extracted protein at different weight tissue:buffer volume 
ratio. Values refer to neutral extraction. 
 
4.3.2 Comparison of chromatographic techniques 
In this work four different chromatografic techniques have been studied for 
separation in first dimention in order to choose the best procedure for the analysis 
of mouse tissue samples.  
In order to compare the performance of the separation methods proposed, was 
compared the total number of identified proteins. It was tried to understand, 
moreover, the various reasons for the differences observed between the various 
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methods, including the resolution power, the orthogonality of the techniques, and 
the loss of sample. (Tab. 7) summarizes the total proteins identified by Mascot 
search engine, for each technique tested. 
As is clear from this table, the largest number of identified proteins was obtained 
by the fractionation of tryptic digested by reversed phase chromatography at high 
pH (pH-RP).  
In addition to the total proteins identified, was considered the total number of 
peptides identified (including redundancy), the total number of unique peptides 
(excluding redundancy), the average amino acid coverage (coverage) and the 
probability of error associated with identification (score). 
While the technique hr-RP Prot is the one that provided the greatest number of 
peptides identified, in agreement with the large number of proteins identified, the 
separation pH-RP has a relatively low number of peptides in total, about half of 
that seen with the hr-RP Prot (2730 vs 5015). Method hr-RP Prot also presents 
coverage amino acids and a higher average score than the pH-RP method. 
Intuitively, these differences should lead to a greater number of proteins identified 
for the technical hr-RP Prot while, as already mentioned, the pH-RP has been the 
technique that has provided, even if slightly, the largest number of proteins 
identified.  
The reason for this is that the pH-RP technique has provided a higher ratio of 
unique peptide compared to peptides total. The ratio of unique to total peptides is 
a measure of how often the instrument fragments the same peptide (MS/MS 
resampling). This resampling causes a loss in duty cycle (the instrument spends 
valuable MS/MS time refragmenting the same peptides) and results in a lower 
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number of protein identifications. The substantially higher percentage of 
unique/total peptides given by the pH-RP method is indicative of a low MS/MS 
resampling rate. So while the hr-RP Prot method yields more total peptides than 
the pH-RP method, the pH-RP method has a higher ratio of unique/total peptides. 
This is due to the hr-RP Prot method having a higher rate of resampling events, 
which results in a lower number of protein hits per peptide sequenced.  
The reason why some methods have such a high rate of resampling the same 
transition is often dependent on mass-spectrometric instrumental parameters, but 
in this study, these parameters were kept constant for all the methodologies as 
well as variations in the resampling are the result separation in the first dimension.  
Regarding the technique SCX according to Dai et al. [145], the elution of peptides 
in the pH mode occurs according to the isoelectric point (pI) of the peptide. 
However, a peptide possessing multiple functional groups with different pKa‘s 
could interact with the SCX resin in amore complex manner, resulting in a peak 
elution profile that is not strictly dictated by isoelectric point. If this were the case, 
then peptides containing fewer ionizable functional groups would elute in a single 
peak while more complex peptides with multiple ionizable groups would elute in 
multiple peaks. However, the interaction between individual peptides and the 
SCX resin is complex and depends on both the pH and ionic strength of the 
elution buffer. 
Based on the results obtained from this study the best technique is the pH-RP. 
This method has allowed the identification of 1338 proteins, of these 82 are 
present in both pools. An overlap of 6.53% provides an estimate of the selectivity 
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of the extraction procedure developed in this work resulting, therefore, be very 
high. 
 
 
Separation 
techniques 
Total 
proteins 
Total 
peptides 
Unique 
peptides 
% 
unique/total 
Av % 
sequence 
coverage 
Av 
protein 
scores 
C8-RP 
Prot 
1267 3485 2341 67.2 13.0 74 
hr-RP 
Prot 
1303 5015 2948 58.8 18.4 97 
SCX 509 1262 971 76.9 10.2 108 
pH-RP 1338 2730 2282 83.6 16.6 88 
 
Tab. 7: Comparison of different separation technique than number of Total 
proteins, Total peptides, Unique peptides identified and than protein identification 
values of Average sequence coverage and Average scores. (N) refer to neutral 
extract; (A) refer to acid extract. 
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4.4 Conclusions  
All techniques examined in this study were suitable for a proteomics study. 
However, each has specific advantages and limitations depending on the available 
equipment, expertise and monetary resources. Peptide separations are easier than 
the protein-based methods owing to simple sample processing, i.e., en masse 
digestion versus digestion of individual fractionations. In addition, protein-level 
separations generally preclude the use of stable isotope labeling for quantitative 
shotgun proteomics. However, the protein-level separations are greater for the 
spectral counting due to the large number of total peptides identified. 
Furthermore, separation of the protein level appear to be larger for smaller 
proteins and are generally more effective at removing residual abundant proteins 
after immunodepletion of serum than peptide HPLC. 
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CHAPTER 6: Concluding remarks 
 
The explosive growth in proteomic research for biomarker discovery, with its 
huge number of samples, demands high throughput, high sensitive, and high 
reproducible LC/MS technologies. In this work, we developed three different 
method able in differential proteomics study. First method was developed for 
serum CA II quantification, a protein present at concentration level about five 
orders of magnitude lower than that of the most abundant proteins, by using nano-
LC-ESI-MS/MS. In addition, using a chromatographic purification step instead of 
a most abundant serum protein depletion kit, protein loss due to aspecific 
interactions with the proteins bonded by antibodies can be avoided. The hardware 
miniaturization introduced by Chip technology has radically reduced analysis time 
and has increased efficiency and sensitivity. Moreover, using this device allows to 
reduce matrix effect; then it is possible to use the external calibration for 
quantification. In second method the protein of interest, CA II, was isolated from 
serum by immunoprecipitation. A proteotypic peptide, produced 
stoichiometrically through proteolysis with trypsin, was ultimately quantified, 
using a synthetic peptide and a structural analogue free-labeled synthetic peptide 
as IS, by LC–ESI–MS/MS in MRM acquisition mode. This strategy, based on 
isolation of target protein by immunoaffinity and its absolute quantification by 
quantifying one of its proteotypic products, could represent a very specific and 
sensitive analytical approach to reach the analytical goal of low-abundance 
protein determination in clinical samples such as serum. Finally third method was 
based on multidimensional chromatography approach applied for a total protein 
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extract analysis. In particular a mouse cardiac tissue was analyzed by high pH LC 
at peptide level coupled with nanoLC-Chip Q TOF mass spectrometer. Moreover 
all techniques examined in this last reserch were suitable for a proteomics study. 
However, each has specific advantages and limitations depending on the available 
equipment, expertise and monetary resources.  
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